

Index

- Aberrant Behavior Checklist (ABC) 294
 Abnormal Involuntary Movements Scale (AIMS)
 147, 293
 academic psychopharmacology 13–14, 21
 acamprosate, alcohol abuse treatment 345, 348,
 350–1, 355–6
 acetylcholine, and Tourette's syndrome 390
 addiction 332
 neurobiologic hypothesis of 345–8
see also substance use disorder (SUD)
 adenylyl cyclase 49
 adjustment disorder with depressed mood
 162
 adrenaline, and pervasive developmental disorder
 277–80
 adrenocorticotrophic hormone (ACTH) 53
 and substance abuse 345
 adverse effects 17
 developmentally determined drug responses
 56–9
see also specific drugs; withdrawal syndromes
 advertising 20–1
 age-related gene expression 107
 aggression 305–22
 animal models 309
 comorbidity 305, 307
 markers of 306–8
 treatment 282, 309–22
 adrenergic drugs 314–16
 anticonvulsant drugs 313–14
 antidepressants 312–13
 antipsychotic drugs 316–17
 anxiolytic medications 311–12
 biopsychosocial approach 320–2
 lithium 309–11
 PRN medications 318–19
 psychostimulants 317–18
 vignettes 319–20
 agonist substitution therapy 351, 359–61
 agoraphobia 188, 189, 190, 192
 comorbidity 192
 treatment 199, 213
 akathisia 149, 205, 316
 alcohol abuse 333–4, 339–40, 343–5, 365
 biologic markers of 340
 comorbidity 366
 fetal alcohol syndrome 56, 60
 teratogenic effects 56, 60
 treatment 125, 345, 348, 350–1, 352–7
 withdrawal syndrome 345, 352–3
see also substance use disorder (SUD)
 alcohol flush reaction 339
 allergies 439
 alprazolam
 abuse potential 356
 anxiety disorder treatment 204, 207, 208, 209,
 213
 generalized anxiety disorder 213
 dosage 204
 panic disorder treatment 189, 199, 207
 amantadine 149, 362
 amenorrhea 151
 amisulpride, pervasive developmental disorder
 treatment 277
 amitriptyline 240
 ADHD treatment 3
 anorexia nervosa treatment 413
 depression treatment 95–6
 amotivational syndrome 205
 amperozide, alcohol abuse treatment 344
 amphetamine 3, 233, 277
 abuse of 340
 ADHD treatment 237
 adverse effects 234
 D-amphetamine 232, 233, 234, 237, 290
 D,L-amphetamine 232, 233, 234, 237
 pervasive developmental disorder treatment
 290
 and tics 389
 amygdala 51
 amyotrophic lateral sclerosis 41
 anorexia nervosa 411–18
 mechanisms 412
 treatment 22, 412–18
 antidepressants 413–14
 antipsychotics 413
 appetite enhancers 414–15
 guidelines 417–18
 lithium 415
 prokinetic agents 415–16
 zinc 416–17
 antibiotic therapy 22, 399
 anticipation, genetic 54–5, 111
 anticonvulsants 19
 adverse effects 60
 aggression treatment 313–14
 bulimia nervosa treatment 419
see also specific drugs

456 Index

- antidepressants 6, 61
 developmentally determined drug response 59
see also monoamine oxidase inhibitors (MAOIs);
specific drugs; specific serotonin reuptake
 inhibitors (SSRIs); tricyclic antidepressants
 (TCAs)
- antimanic treatment 118–21
- antiparkinsonian agents 147–8, 149–50
- antisocial personality disorder (ASPD) 335, 361
- anxiety disorders 187–219, 439, 441–2
 assessment 214–15
 behavioral variables amenable to
 pharmacotherapy 82
 central nervous system mechanisms 194–8
 classification 188–9
 comorbidity 162, 192–3, 214–15
 ADHD 210
 aggression 307
 asthma 439–40
 substance abuse 356–7, 361
 diagnosis 188, 190–1
 mental status chart 80–1
 epidemiology 189–94
 treatment 87, 125, 203–19, 356–7
 adults 198–203
 benzodiazepines 125, 189, 195–6, 198, 207–8,
 218
 buspirone 200, 204, 210–11, 357
 duration and tapering of 218–19
 guidelines 214–19
 moclobemide 211
 prepharmacologic interventions 216–17
 SSRIs 125, 189, 203–7, 218, 356–7
 TCAs 199, 208–10, 218
 venlafaxine 212
see also generalized anxiety disorder (GAD);
 panic disorder; separation anxiety disorder
 (SAD); social phobia
- apoptosis 40–1
- appetite enhancers, anorexia nervosa treatment
 414–15
- Asperger's syndrome 138, 266, 268, 270–1
 central nervous system mechanisms 273, 275
 diagnosis 269
 treatment 280–1
see also pervasive developmental disorder (PDD)
- asthma 439–40, 442, 449
- attention-deficit/hyperactivity disorder (ADHD) 1,
 62, 230–52, 449
 aggression in 305, 306, 312, 317–18
 behavioral variables amenable to
 pharmacotherapy 82
 candidate genes 55–6
 comorbidity 232
 anxiety disorder 210, 232
 bipolar mood disorder 110, 125
 conduct disorder 232
 impact on pharmacotherapy 247–9
 learning disorder 232
 substance abuse 367
 Tourette's syndrome 383, 385, 400
 diagnosis 73, 74
 differential diagnosis 107
 mental status chart 79
 misdiagnosis 109
 MRI studies 52
 nicotinic hypothesis 251–2
 pathophysiology 230–1
 pseudoADHD 214
 treatment 87, 232–52, 383
 antidepressants 3, 4, 240–5
 antipsychotics 245
 combined pharmacotherapy 249–50
 comorbidity impact 247–9
 fatty acids 22–3
 future directions 251–2
 and growth deficits 238–9
 interdose rebound 239–40
 overtreatment 11
 psychostimulants 1–3, 58, 232–40, 400
- autistic disorder 265–6, 270
 behavioral variables amenable to
 pharmacotherapy 82
 central nervous system mechanisms 273, 275,
 276, 280
 diagnosis 268
 differential diagnosis 138–9, 164
 Kanner's autism 265, 266
 treatment 4, 5, 9, 285–6, 288–90, 316
 adults 280–3
 clonidine 315
 naltrexone 16–17, 280, 290–1
 venlafaxine 212
see also pervasive developmental disorder (PDD)
- avoidant disorder 188, 190, 193
 treatment 207, 213
- basal ganglia 438, 440
 and substance abuse 341
 and Tourette's syndrome 387–8
- behavior disorders 3–4, 6
- behavioral inhibition 198, 439
- Behavioral Summarized Evaluation 277
- benign childhood epilepsy 22
- benzotropine 148, 149
- Benzedrine® 1
- benzodiazepines 60
 abuse potential 356, 365
 adverse effects 208, 352
 aggression treatment 311
 anxiety disorder treatment 125, 195–6, 198, 200,
 207–8
 dosage 204
 generalized anxiety disorder 189, 201, 202
 tapering of 218
 bipolar disorder treatment 121
 panic disorder treatment 189, 199, 207, 208
 schizophrenia treatment 148
 substance abuse treatment 350, 352
 tic suppression 397

457 Index

- Berksonian bias 432
 beta blockers
 aggression treatment 314–15
 pervasive developmental disorder treatment 289–90
 see also specific drugs
 beta-hemolytic streptococcal (GABHS) infection 168
 and Tourette's syndrome 391, 398
 binge eating disorder 410, 425
 bingeing 418
 see also bulimia nervosa
 biofeedback 399
 bipolar mood disorder (BMD) 55, 98, 106–27, 437
 comorbidity 110–11, 125, 248, 364
 developmental issues 107–8
 diagnosis 106–7
 differential diagnosis 107, 137
 misdiagnosis 109–10
 underdiagnosis 109–10
 epidemiology 106
 etiology 111–15
 cognition 113–14
 electrophysiology 113
 family functioning 115
 genetics 111
 laterality 112
 neuroimaging 112–13
 psychosocial factors 114–15
 presentation 108–9
 treatment 19, 115–27
 bipolar depression 121–3
 with comorbid conditions 125
 female-specific issues 123–4
 light therapy 21
 lithium 8, 364
 maintenance treatment 126–7
 nutritional therapy 23
 psychoeducation/psychotherapy 117–18, 126–7
 therapeutic relationship establishment 115–17
 see also bipolar disorder; mania
 body dysmorphic disorder (BDD) 164
 borderline personality disorder/traits 316
 differential diagnosis 138
 borderline syndrome of childhood 165
 botulinum toxin, tic suppression 397
 brain development 49–52, 59–60, 61–2
 plasticity and sensitive periods 39–40
 see also development; neural development
 brain injury 164, 438
 and aggression 305
 perinatal 433–6
 brain reward regions 340
 breast-feeding 124
 Brief Psychiatric Rating Scale (BPRS) 118, 146, 156, 208
 bromocriptine
 pervasive developmental disorder treatment 277
 substance abuse treatment 343, 354, 362
 bufaramine, social phobia treatment 201
 bulimia nervosa 418–25
 mechanisms 419
 treatment 419–25
 anticonvulsants 419
 antidepressants 421–2
 guidelines 424–5
 lithium 420
 opiate antagonists 420
 psychotherapy 422–4
 serotonergic agents 420
 buprenorphine, substance abuse treatment 348, 351, 357, 362
 bupropion 100, 125, 235
 ADHD treatment 242, 367
 adverse effects 235, 242, 421
 depression treatment 96
 substance abuse treatment 362, 364
 buspirone 177, 201, 278
 ADHD treatment 247
 adverse effects 211, 247
 aggression treatment 311–12
 anxiety disorder treatment 200, 204, 210–11, 357
 generalized anxiety disorder 201, 202, 210, 213
 dosage 204
 pervasive developmental disorder treatment 276, 278, 282, 286
 substance abuse treatment 344, 354, 357
 calcium carbimide, alcohol abuse treatment 355
 cannabinoid receptor 345
 cannabis use 333
 carbamazepine 5–6, 286
 ADHD treatment 247
 adverse effects 120, 247
 aggression treatment 313
 bulimia nervosa treatment 419
 mania treatment 120
 pervasive developmental disorder treatment 289
 substance abuse treatment 352–3, 362
 teratogenic risks 124
 carbon dioxide sensitivity 442
 cerebellum, and pervasive developmental disorder 274–5
 Child Behavior Checklist 72
 Child Symptom Inventory 72
 Childhood Autism Rating Scale (CARS) 294
 Childhood Behavior Checklist (CBCL) 306–7
 childhood disintegrative disorder 268, 271
 Children's Global Assessment Scale (CGAS) 294
 Children's Psychiatric Rating Scale (CPRS) 310
 chlordiazepoxide 5
 adverse effects 208
 anxiety disorder treatment 207
 substance abuse treatment 352
 chlorpromazine 4, 144
 adverse effects 144
 anorexia nervosa treatment 413
 mania treatment 118
 schizophrenia treatment 147

458 Index

- cholecystokinin (CCK)
 and anxiety 196
 and substance abuse 345
- choline 49–50
- cigarette smoking 333
 nicotine withdrawal treatment 350, 363–4
see also substance use disorder (SUD)
- cisapride
 adverse effects 416
 anorexia nervosa treatment 415, 416
- citalopram 96, 235, 244, 283
 adverse effects 235
 metabolism 99
 pervasive developmental disorder treatment 286
 substance abuse treatment 354
- Clinical Global Impressions (CGI) scale 208, 281
- clinical uncertainty 9–10
- Clinician-Rated Visual Analog Scale 317
- clobazam, aggression treatment 311
- clocinnamox, substance abuse treatment 348
- clomipramine 278, 283
 adverse effects 172
 anorexia nervosa treatment 413
 anxiety disorder treatment 204, 209–10
 dosage 204, 281
 obsessive–compulsive disorder treatment 169,
 172–3, 177
 panic disorder treatment 199
 pervasive developmental disorder treatment 276,
 278, 280–1, 283–5, 293
- clonazepam 235
 adverse effects 208, 235
 anxiety disorder treatment 204, 207, 208, 213
 dosage 204
 obsessive–compulsive disorder treatment 177
 panic disorder treatment 189, 199, 207, 208
 schizophrenia treatment 148, 149
- clonidine 6, 7, 238, 277
 ADHD treatment 245–6, 367
 adverse effects 18, 213, 246, 283, 357–8
 aggression treatment 315, 320
 and anxiety 195
 combined medication 18
 developmentally determined response 57
 dosage 204
 pervasive developmental disorder treatment 283,
 290
 post-traumatic stress disorder treatment 193–4,
 212, 214
 substance abuse treatment 350, 352, 357–8, 364
 tic suppression 177, 390, 394, 396
- clonitoxol, mania treatment 118
- clorgyline, ADHD treatment 243
- clozapine 52, 144, 151, 277
 adverse effects 289
 aggression treatment 317
 pervasive developmental disorder treatment 276,
 282, 288–9, 293
 schizophrenia treatment 143, 152, 366
 tic suppression 393
- cocaine 58–9
 abuse 340, 342, 346, 348, 361–3
 teratogenic effects 56
 withdrawal management 361–2
- cognitive impairment, bipolar mood disorder
 113–14
- cognitive–behavioral therapy (CBT)
 anxiety disorder 217
 bipolar mood disorder 118
 bulimia nervosa 423–4
 obsessive–compulsive disorder 170–1, 178
- compulsions 160–1, 164
see also obsessive–compulsive disorder (OCD)
- conduct disorder (CD)
 aggression in 305, 312
 behavioral variables amenable to
 pharmacotherapy 82
 comorbidity 110, 232, 248, 364
 differential diagnosis 107
- confidentiality 74
- Connors Abbreviated 10-Item Teacher Rating Scale
 318
- Connors Parent Rating Scale 72
- Connors Parent Teacher Questionnaire 277
- Continuous Performance Test (CPT) 317
- coprolalia 384, 397
- corpus callosum 51
- corticosteroids 399
- corticotrophin-releasing factor (CRF) 53
 and anxiety 195
- creatine 50
- cyclothymia 107
- cyproheptadine, anorexia nervosa treatment 414–15
- deep white-matter hyperintensities (DWMH) 113
- delirium 140
- delusions 265, 266
 mood disorders 137
 schizophrenia 135, 141
 and substance abuse 137
 treatment 148
- dementia 140, 313
 premature 142
- dependence syndrome 330–2
see also substance use disorder (SUD)
- depression 6, 91–102, 113, 137, 439
 at-risk children/adolescents 92
 behavioral variables amenable to
 pharmacotherapy 82
 in bipolar mood disorder 108
- central nervous system mechanisms 95
- comorbidity
 anorexia nervosa 411
 anxiety disorders 192–3, 202–3
 pervasive developmental disorder 283
 substance abuse 335
- course of illness 91–2
- diagnosis 92–5
 differential diagnosis 153
 mental status chart 80–1

459 Index

- postpartum depression 124
 treatment 4, 6, 87, 95–101
 adults 95–7
 bipolar depression 121–3
 clinical guidelines 100–1
 SSRIs 7, 87, 96–101
 TCAs 16, 95–101
 venlafaxine 212
see also major depressive disorder
- dermatitis, atopic 439
- desipramine 234, 240
 ADHD treatment 3, 240–1, 248
 combined pharmacotherapy 249–50
 adverse effects 17–18, 234
 sudden death 241–2
- bulimia nervosa treatment 423, 424
- combined medication 15
- depression treatment 96
- pervasive developmental disorder treatment 285
- substance abuse treatment 362, 364
- desmethylsertraline 99
- development
 macrodevelopment 49–52
 microdevelopment 38–49
 apoptosis 40–1
 cellular migration and growth 41–2
 coupling 49
 models and concepts 38–9
 neuropeptides 47–9
 neurotransmitters 42–4
 plasticity and sensitive periods 39–40
 receptors 44–7, 61–2
 stress effects 53–4
see also brain development; neural development
- developmental psychopharmacology 56–9
- dexedrine 125
- diagnosis 71
 information gathering 72–83
 interview with child 77–8
 parental interview 76–7
see also specific disorders
- Diagnostic Interview for Children and Adolescents–Revised (DICA–R) 107
- Diagnostic Interview Schedule for Children (DISC) 107, 307
- diazepam, substance abuse treatment 352
- diencephalon, and pervasive developmental disorder 275
- diffusion tensor imaging (DTI) 52
- diphenhydramine 4, 5, 149
- dissociative disorder 138
- distractibility 290
- disulfiram, substance abuse treatment 351, 355
- divalproex sodium (DVP)
 adverse effects 120
 bipolar disorder treatment 122, 126
 mania treatment 119, 120
 teratogenic risks 124
- dizocilpine 345
- L-dopa 277
- dopamine 44, 46
 and pervasive developmental disorders 276–7
 receptors 45, 46–7
 and substance abuse 340, 342–3
 and Tourette’s syndrome 389
- dopamine transporter gene (DAT1) 55
- doxepine 240, 364
- drug abuse *see* substance use disorder (SUD)
- drug advertising 20–1
- dysphoric mania 118
- dysthymia 107, 121, 192, 366
- dystonias 149, 205
- eating disorders 410
 binge eating disorder 410
 differential diagnosis 164
see also anorexia nervosa; bulimia nervosa
- Ebstein’s cardiac anomaly 124
- echolalia 384
- effectiveness 14–15
- efficacy 14–15
- elective mutism 191
 treatment 211
see also selective mutism
- electroconvulsive therapy (ECT) 21
 depression 96, 123
 mania 118
 schizophrenia 153–4
- emotional circuits, and substance abuse 341
- empirical treatments 10, 11–12
- encephalins, and substance abuse 344
- endorphins, and substance abuse 344
- enuresis 4, 16
- epidermal growth factor 49
- epilepsy 314, 436–7
 differential diagnosis 139–40
- ethanol
 teratogenic effects 56, 60
see also alcohol abuse
- ethical issues 9–10
- evidence-based medicine 11–12
- exposure and response prevention (E/RP) 170–1
- extrapyramidal side effects 17, 57–8, 144, 150, 287–8
 prophylaxis 147–8
 SSRIs 205–6
- Extrapyramidal Symptom Rating Scale (ESRS) 147, 293
- Family Adaptability and Cohesion Evaluation Score (FACES II) 115
- family issues, bipolar mood disorder 115
- family therapy, obsessive–compulsive disorder 170
- fascilins 42
- fatty acids, ADHD treatment 22–3
- fenfluramine
 adverse effects 286
 bulimia nervosa treatment 420
 pervasive developmental disorder treatment 276, 286
 prolactin response, and aggression 306, 307

460 Index

- fetal alcohol syndrome 56, 60
 fibroblast growth factor (FGF) 48
 flumazenil, substance abuse treatment 353
 fluoxetine 57, 96, 244, 283
 ADHD treatment 235, 244
 combined pharmacotherapy 250
 adverse effects 99, 205, 235
 aggression treatment 312–13, 320
 anorexia nervosa treatment 413–14
 anxiety disorder treatment 204, 213
 bulimia nervosa treatment 421, 423, 424, 425
 depression treatment 53, 59, 98, 101, 122
 major depression 7, 351, 356, 364
 dosage 176, 204, 207
 metabolism 99, 174, 206
 obsessive–compulsive disorder treatment 172, 173–4
 panic disorder treatment 199, 207
 pervasive developmental disorder treatment 276, 278, 281–2, 285–6
 post-traumatic stress disorder treatment 202
 selective mutism treatment 213
 social phobia treatment 201
 substance abuse treatment 351, 354, 356, 362, 364
 withdrawal syndrome 175
 flupenthixol, borderline personality disorder treatment 316
 fluphenazine, tic suppression 393, 395
 flutamide, tic suppression 397–8
 fluvoxamine 96, 235, 244, 278, 283
 adverse effects 235
 aggression treatment 313
 anxiety disorder treatment 204, 214
 bulimia nervosa treatment 422
 dosage 204, 207
 metabolism 99, 174, 175
 obsessive–compulsive disorder treatment 172, 173, 174
 panic disorder treatment 199, 207
 pervasive developmental disorder treatment 276, 278, 281, 286
 social phobia treatment 201
 substance abuse treatment 354
 withdrawal syndrome 206
 focal brain lesions 446–7
 fragile X syndrome 55

 G proteins 49
 GABA (gamma-aminobutyric acid) 47–8
 and anxiety 195–6
 receptor 48
 and substance abuse 344–5, 355–6
 and Tourette's syndrome 390–1
 gabapentin 314
 GABHS (beta-hemolytic streptococcal infection) 168
 galactorrhea 151
 gamma hydroxybutyric acid, alcohol abuse treatment 345, 356

 gene therapy 22
 generalized anxiety disorder (GAD) 187, 188–9, 192
 comorbidity 125, 192, 202, 203, 214
 diagnosis 190
 epidemiology 189
 treatment 200, 213–14, 217, 218
 adults 201–2
 buspirone 210
 SSRIs 203–5
 TCAs 210
 venlafaxine 212
 see also anxiety disorders
 genetic anticipation 54–5, 111
 globus pallidus 51, 52
 glucocorticoids 53, 54
 glutamate 47–8, 50
 and substance abuse 344–5
 and Tourette's syndrome 390
 growth deficits, and ADHD treatment 238–9
 guanabenz, substance abuse treatment 358
 guanfacine 235
 ADHD treatment 246
 adverse effects 235
 aggression treatment 315–16
 substance abuse treatment 358
 tic suppression 177, 390, 394, 396–7
 gynecomastia 151

 habit reversal training (HRT) 399
 hallucinations 265, 266
 epilepsy 139
 mood disorders 137
 bipolar mood disorder 108
 post-traumatic stress disorder 138
 schizophrenia 135, 141
 and substance abuse 137
 treatment 148
 haloperidol 60–1, 144, 277
 adverse effects 287–8, 316, 394–5
 aggression treatment 316–17
 obsessive–compulsive disorder treatment 177
 pervasive developmental disorder treatment 287, 293
 schizophrenia treatment 148
 tic suppression 382, 393, 394–5
 Hamilton Anxiety Scale 208, 215
 head injury 438, 447
 see also brain injury
 headache 437
 heart period variability (HPV) 307
 hippocampal neurogenesis, stress effects 54
 history taking 72–83
 baseline assessment for treatment 78–83
 interview with child 77–8
 parental interview 76–7
 homovanillic acid (HVA), and pervasive developmental disorder 276–7
 Hopkins Motor and Vocal Tic Scale 392
 5-HT *see* serotonin
 Huntington's chorea 55, 166

461 Index

- hyperprolactinemia 151
 hypochondriasis 164
 hypothyroidism 449
- imipramine 5, 6, 234, 240
 ADHD treatment 3
 adverse effects 201, 234
 anxiety disorder treatment 204, 209–10, 213, 356
 generalized anxiety disorder 201–2, 210
 bulimia nervosa treatment 422–3
 depression treatment 95–6, 97, 98, 356, 361
 dosage 204
 panic disorder treatment 188, 199
 pervasive developmental disorder treatment 290
 platelet binding, and aggression 307
 substance abuse treatment 356, 361
- innovative treatments 21–3
 insomnia *see* sleep disturbance
 insulin-like growth factor 49
 intellectual disability, psychosis in 136
 intermittent explosive disorder 312, 321
 interpersonal therapy (IPT), bipolar mood disorder 117–18
 Interview for Childhood Disorders and Schizophrenia (ICDS) 141
 intracerebral metabolic rates for glucose utilization (ICMRGlc) 50
 intravenous immunoglobulin therapy 22, 399
 involuntary treatment 146
- Kanner's autism 265, 266
 Kennard effect 39
 kindling 91, 437
 Kleine–Levin syndrome 309
- lamotrigine
 adverse effects 17
 and aggression 314
 bipolar disorder treatment 121, 122, 125
 language disorders 74
 laterality, and bipolar mood disorder 112
 learning disorders 74
 comorbidity 232, 386
 social learning disorders 236
 length of treatment 87–8
 levoalpha acetylmethadol (LAAM), substance abuse treatment 351, 360–1
 light therapy, bipolar disorder 21, 122–3
 limbic–hypothalamic–pituitary–adrenal (LHPA) axis, stress effects 53
 limbic system
 and pervasive developmental disorder 275
 and substance abuse 341
- lithium 60, 85
 adverse effects 119–20, 310–11
 aggression treatment 309–11, 321
 anorexia nervosa treatment 415
 bipolar disorder treatment 126, 364
 and breast-feeding 124
 bulimia nervosa treatment 420
 depression treatment 96, 99, 122
 history of use 5, 6, 7, 8
 mania treatment 119
 pervasive developmental disorder treatment 289
 substance abuse treatment 125, 354, 364
- locus coeruleus
 and anxiety 194, 195
 and substance abuse 342, 346
- lofexidine, substance abuse treatment 350, 352, 358
 long night treatment 121
 long Q-T syndrome 18
- lorazepam
 abuse potential 356
 mania treatment 118
 schizophrenia treatment 148
- loxapine 144
 schizophrenia treatment 148
- lysergic acid diethylamide (LSD) 5
 lysosomal storage disease 140
- magnesium pemoline *see* pemoline
 major depressive disorder 6, 7, 8, 438
 and anorexia nervosa 413
 comorbidity
 ADHD 250
 anxiety disorders 192–3
 obsessive–compulsive disorder 162
 substance abuse 351, 356, 361, 364–5, 366
 treatment 86, 351, 356, 364
see also depression
- mania 100, 106, 112
 behavioral variables amenable to pharmacotherapy 82
 in bipolar mood disorder 108
 comorbidity 248–9
 mental status chart 80–1
 and SSRIs 205
 treatment 87, 118–21
see also bipolar mood disorder (BMD)
- Mania Rating Scale 107
 marijuana use 333
 mazindol 363
 median raphe, and substance abuse 342
- medical evaluation 444–9
 endocrine disorders 448–9
 focal brain lesions 446–7
 respiratory illness 449
 seizure disorders 448
- medication advertising 20–1
 medication selection 84–7
 Medication-Specific Side Effect Scale (MSSSES) 147, 156
- mental retardation
 aggression in 305, 312, 314
 and autism 270, 282
 behavioral variables amenable to pharmacotherapy 82
 differential diagnosis 164
 mental status chart 79–81
- meprobamate 4

462 Index

- metaclopramide
 adverse effects 416
 anorexia nervosa treatment 415
- methadone 344, 350, 351, 357, 359–60, 361
- methylphenidate 125, 232, 233, 234
 abuse of 58–9
 ADHD treatment 237, 249–50
 adverse effects 18, 58–9, 234
 aggression treatment 317–18
 combined medication 15, 18, 249–50
 pervasive developmental disorder treatment 290
 and tics 389
- methysergide 279
 pervasive developmental disorder treatment 276, 279
- metoprolol, aggression treatment 315
- mirtazapine, depression treatment 97
- mitochondrial DNA damage 107
- mixed states 118
- MK-801, alcohol withdrawal treatment 345
- moclobemide 243
 adverse effects 211
 anxiety disorder treatment 204, 211
 dosage 204
 post-traumatic stress disorder treatment 202
 social phobia treatment 201, 213
- Modified Mania Rating Scale (MMRS) 118
- money-oriented medicine 11–12
- monoamine oxidase inhibitors (MAOIs) 4, 95, 234
 ADHD treatment 243–4
 adverse effects 234, 243–4
 anxiety disorder treatment 199, 200
 depression treatment 95, 96, 98–9
 drug interactions 210, 243–4
 post-traumatic stress disorder treatment 202
 social phobia treatment 201
- mood disorders 6
 aggression in 305
 comorbidity 192, 232
 differential diagnosis 137
see also bipolar mood disorder (BMD)
- mood stabilizers 19, 122
 mania treatment 119
 postpartum depression prevention 124
 teratogenic risks 123–4
- morphine abuse 346, 348
- MPP (1-methyl-phenyl-pyridium) 41
- Multidimensional Anxiety Scale for Children (MASC) 215
- multiplex developmental disorder 165
- N-acetyl aspartate (NAA) 49–50
- nadolol 277
 ADHD treatment 246–7
 aggression treatment 314–15
 pervasive developmental disorder treatment 282
- NAIP (neuronal apoptosis inhibitory protein) 41
- nalmefene, substance abuse treatment 353–4
- naloxone, alcohol abuse treatment 344
- naltrexone
 autistic disorder treatment 16–17, 280, 283, 290–1
 substance abuse treatment 344, 350, 353, 358–9, 364
- nefazodone 282
 adverse effects 17
 depression treatment 96
 metabolism 99
- neural development 38–9, 61–2
 apoptosis 40–1
 cellular migration and growth 41–2
 hippocampal neurogenesis, stress effects 54
 neuropeptide role 47–9
see also development
- neuroglial 42
- neuroleptic malignant syndrome 58, 150, 176
- neuroleptics 5, 21, 61, 143–4
 adverse effects 17, 58, 144–5, 149–51, 156, 287–8
 anticholinergic side effects 150–1
 dystonias 149
 neuroleptic malignant syndrome 58, 150
 parkinsonian side effects 58, 61, 149–50
 atypical neuroleptics 17, 61, 143–5, 151–3, 288
 introduction of 9, 19
 pervasive developmental disorder treatment 287–9
 schizophrenia treatment 147–8, 151–3
 depot injections 154–5
see also specific drugs
- neuropeptides 47–9
 neuropeptide Y, and anxiety 196
 and pervasive developmental disorder 280
- neurotensin 48
- neurotransmitters
 development 42–4
 and pervasive developmental disorders 276–80
 and substance abuse 342–5
see also specific neurotransmitters
- nicotine withdrawal treatment 350, 363–4
- nicotinic drugs, ADHD treatment 251–2
- N-methyl-D-aspartate (NMDA) receptors 39, 48, 54
 and alcohol abuse 345
- noradrenaline
 and pervasive developmental disorder 277–80
 and substance abuse 343
 and Tourette's syndrome 389–90
- norfluoxetine metabolism 99
- nortriptyline 234, 240
 ADHD treatment 240, 241
 adverse effects 234
 depression treatment 96
- nutrition-based medicine 22–3
- obsessions 160–1, 164
- obsessive difficult temperament 165
- obsessive-compulsive disorder (OCD) 159–79, 192, 438, 440–1
 age effects 162
 comorbidity 125, 162–3, 167–8, 283–5
 tics 161, 162–3, 167, 383, 385–6, 401
 course of illness 161–2

463 Index

- diagnosis 163–5, 190
 - differential diagnosis 139, 164
 - mental status chart 79
- drug-induced 17
- epidemiology 159–60
- etiology 165–9
 - genetic basis 168
 - serotonin hypothesis 166–7
- gender effects 162
- symptoms 160–1
- treatment 22, 169–78, 401
 - augmentation strategies 177
 - behavioral treatment 170–1, 178
 - clomipramine 172–3, 177
 - dosage 176
 - duration of 176–7
 - family therapy 170
 - psychodynamic psychotherapy 170
 - selection of 178
 - SSRIs 173–6, 203, 205
- obsessive–compulsive personality disorder (OCPD) 165
- olanzapine 144, 277, 279
 - adverse effects 119
 - aggression treatment 317
 - mania treatment 119
 - pervasive developmental disorder treatment 279, 282
 - schizophrenia treatment 152, 366
- oppositional defiant disorder (ODD)
 - aggression in 305
 - mental status chart 79
- Over Aggression Scale 314
- overanxious disorder (OAD) 188, 190
 - epidemiology 189
 - treatment 207, 208, 213
 - see also* anxiety disorders
- overfocusing 237
- overtreatment 11
- oxytocin 48, 280

- palilalia 384
- PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections) 168–9, 438, 440–1
- panic disorder 187, 188–9, 192, 441–2, 443
 - central nervous system mechanisms 194–5, 446–7
 - comorbidity 125, 192, 203
 - diagnosis 190
 - epidemiology 189–92
 - treatment 200, 205, 207, 208, 213, 217
 - adults 199–201, 203
- panic-like hyperventilation syndrome 212
- pargyline, ADHD treatment 243
- Parkinson's disease 41, 166
- paroxetine 53, 96, 244, 283
 - ADHD treatment 235
 - adverse effects 205, 235
 - depression treatment 98, 101, 122
 - dosage 204, 207
 - generalized anxiety treatment 201–2, 214
 - metabolism 99, 174, 175, 206
 - obsessive–compulsive disorder treatment 52, 173, 174
 - panic disorder treatment 199–201, 207
 - pervasive developmental disorder treatment 278, 286
 - social phobia treatment 201
 - withdrawal syndrome 175, 206
- pemoline 232, 233, 234
 - ADHD treatment 237
 - adverse effects 234, 238
 - and tics 389
- pentagastrin, and anxiety 196
- pergolide, tic suppression 398
- periventricular hyperintensities (PVH) 113
- perphenazine 4
 - schizophrenia treatment 148
- personality disorders
 - antisocial personality disorder 335, 361
 - borderline personality disorder/traits 138, 316
 - comorbidity 111
 - obsessive–compulsive personality disorder 165
 - schizotypal personality disorder 134, 138–9
 - treatment 312
- pervasive developmental disorder (PDD) 134, 265–95
 - aggression in 305
 - assessment 291–3
 - behavioral variables amenable to pharmacotherapy 82
 - central nervous system mechanisms 271–80
 - neuroanatomic changes 274–5
 - neurocognitive deficits 273
 - neurotransmitter changes 276–80
 - theoretical concepts 272–3
 - comorbidity 283
 - diagnosis 267–9
 - differential diagnosis 138–9, 164
 - mental status chart 80–1
 - negative symptoms 266, 267
 - positive symptoms 266, 267
 - treatment 280–95, 316
 - adults 280–3
 - baseline evaluations 293–4
 - choice of 293
 - inadequate clinical response 294
 - initiation of 294
 - long-term treatment 294–5
 - monitoring of 294
 - neuroleptics 287–9
 - opioid antagonists 290–1
 - serotonin transport inhibitors 280–2, 283–6
 - stimulants 290
 - sympatholytic agents 289–90
 - thymoleptics 289
 - see also* autistic disorder
- pharmaceutical advertising 20–1

464 Index

- phenelzine 234, 243
 adverse effects 234
 elective mutism treatment 211
 panic disorder treatment 199
 social phobia treatment 201
- phenobarbital 3
 adverse effects 60
- phenytoin 4
 bulimia nervosa treatment 419
- phobic disorders 4
 comorbidity 162
 diagnosis 190
 epidemiology 189, 193
 treatment 214
see also agoraphobia; school phobia; social phobia
- phosphocreatine 50
- phospholipase C 49
- pimozide 277
 anorexia nervosa treatment 413
 pervasive developmental disorder treatment 287
 tic suppression 177, 393, 395
- pindolol 177
 ADHD treatment 246
 adverse effects 246
 depression treatment 96–7
- plasmapheresis 22, 399
- plasticity, developmental 39–40
- platelet-derived growth factor 49
- polycystic ovary disease 17, 120, 123
- polypharmacy 15–16
- Positive and Negative Symptom Scale for Schizophrenia (PANSS) 146, 266
- postpartum depression 124
- post-traumatic stress disorder 193–4
 aggression in 305, 320
 comorbidity 202–3
 diagnosis 190
 differential diagnosis 138
 prevalence 194
 treatment 200, 212, 214
 adults 202–3
- Prader–Willi syndrome 281
- prefrontal cortex, and pervasive developmental disorder 274
- pregnancy, and bipolar mood disorder 123–4
- PRN (pro re nata) medications 318–19
- procyclidine 148, 149
- propranolol 6, 149, 235, 277
 ADHD treatment 246
 adverse effects 235
 anxiety disorder treatment 204, 212
 dosage 204
 pervasive developmental disorder treatment 282, 289–90
 post-traumatic stress disorder treatment 214
 substance abuse treatment 352
- protein phosphorylation, and substance abuse 346–7
- protriptyline 240
- psychoeducation
 anxiety disorder 216
 bipolar mood disorder 117, 126–7
 tic disorders 392–3, 399–400
- psychosis
 aggression in 305
 behavioral variables amenable to pharmacotherapy 82
 in intellectually disabled children/adolescents 136
- psychostimulants 4, 6–7
 abuse of 239
 ADHD treatment 1–3, 58, 232–40
 combined pharmacotherapy 250
 adverse effects 17, 237–8
 growth deficits 238–9
 tic disorders 239, 400
 aggression treatment 317–18
 pervasive developmental disorder treatment 290
- psychotherapy
 bipolar mood disorder 117–18, 126–7
 bulimia nervosa 422–4
 obsessive–compulsive disorder 170
- quantitative trait loci (QTL) genetic mapping 339
- rapid cycling 118, 121
- rash 17
- reboxetine 53
- receptors
 blockade 143–5
 development 44–7, 61–2
- referral bias 432
- relaxation training 399
- remeron, depression treatment 101
- research, academic 13–14, 21
- reserpine 4, 41
 induction of depression 95
- respiratory illness 439–40, 441–2, 449
 asthma 439–40, 442
- restless leg syndrome 398
- Restricted Academic Playroom observation 73
- Rett's syndrome 22, 268, 271
- Revised Children's Manifest Anxiety Scale (RCMAS) 215
- reward pathways, and substance abuse 340–1
- rhythm stability hypothesis 117
- risperidone 144, 277, 278, 286
 adverse effects 119, 288
 aggression treatment 317
 mania treatment 119
 obsessive–compulsive disorder treatment 177
 pervasive developmental disorder treatment 276, 278, 288, 293
 schizophrenia treatment 152
 tic suppression 393
- ritanserin 282
 alcohol abuse treatment 344, 354

465 Index

- Scale for the Assessment of Negative Symptoms (SANS) 266
- Schedule for Affective Disorders and Schizophrenia for School-Aged Children (K-SADS) 93–5, 107, 118, 141
- schizoaffective disorder 137
- schizoid personality 165
- schizophrenia 55, 61, 134–57
 behavioral variables amenable to pharmacotherapy 82
 characteristics 135–6
 comorbidity 366
 diagnosis 134, 135, 140–1
 differential diagnosis 107, 113, 136–40, 265–6
 mental status chart 79
 misdiagnosis 109–10
 early-onset schizophrenia (EOS) 135–6
 etiologic theories 142–3
 genetics 143
 neurodegenerative theories 142
 neurodevelopmental theories 142
 negative symptoms 135, 153, 266, 267
 positive symptoms 135, 266, 267
 treatment 52, 85, 146–56
 acute or initial presentation 146–8, 153–4
 adults 143–5
 atypical neuroleptics 151–3
 electroconvulsive therapy 153–4
 intermediate and long-term management 154–6
 involuntary treatment 146
 relapses 155–6
 very early-onset schizophrenia (VEOS) 135–6
 schizotypal personality disorder 134
 differential diagnosis 138–9
 school phobia/refusal 5, 189, 215
 treatment 207, 209, 211, 213
 seasonal affective disorder, light therapy 21
 second messenger systems 49
 and Tourette's syndrome 391
 seizures 140, 152, 448
 selective mutism 188, 191, 193
 treatment 203, 213
 selective serotonin reuptake inhibitors *see* specific serotonin reuptake inhibitors
 selegiline 234
 ADHD treatment 243
 adverse effects 234
 self-harm 118, 311–12
 treatment 282–3, 312–13, 314
see also suicide
 Self-Injurious Behavior Questionnaire 317
 sensitisation 332
 sensitive periods, developmental 39–40
 separation anxiety disorder (SAD) 6, 192, 198, 442
 diagnosis 190
 mental status chart 80–1
 epidemiology 189
 treatment 5, 7, 208, 209, 213
 seroquel 144, 282
 serotonin 43–4, 442–3
 and aggression 307, 308
 and anxiety 195
 and bulimia nervosa 420
 and pervasive developmental disorder 276
 receptors 45–6
 and social phobia 201
 and substance abuse 343–4
 and Tourette's syndrome 390
 serotonin reuptake inhibitors (SRIs)
 obsessive–compulsive disorder treatment 166–7, 172
 augmentation strategies 177
 withdrawal syndrome 174–5
see also specific serotonin reuptake inhibitors (SSRIs)
 serotonin syndrome 175–6, 206, 210, 211, 313
 sertindole 282
 sertraline 96, 235, 244, 278, 283
 ADHD treatment 250
 adverse effects 205, 235
 dosage 176, 207
 metabolism 99, 174
 obsessive–compulsive disorder treatment 172, 173, 174
 panic disorder treatment 199, 207
 pervasive developmental disorder treatment 276, 278, 281, 285, 286
 social phobia treatment 201
 sexual dysfunction
 neuroleptic side effects 151
 SSRI adverse effects 100
 side effects *see* adverse effects
 sleep disturbance 121
 treatment 209–10, 214
 smoking *see* cigarette smoking; substance use disorder (SUD)
 social learning disorders 236
 social phobia 187, 188
 comorbidity 125, 192
 diagnosis 190
 mental status chart 80–1
 epidemiology 193
 treatment 200, 201, 218
 social rhythm therapy, bipolar mood disorder 117
 specific serotonin reuptake inhibitors (SSRIs) 61, 87, 235
 ADHD treatment 244
 combined pharmacotherapy 250
 adverse effects 99–100, 174, 205–6, 207, 235
 aggression treatment 312–13, 321
 anorexia nervosa treatment 413–14, 417
 anxiety disorder treatment 125, 200, 203–7, 218, 356–7
 generalized anxiety disorder 189, 201–2, 203–5, 214
 bulimia nervosa treatment 421, 425
 depression treatment 98, 99–100, 101, 122
 adults 96–7
 developmentally determined drug response 59

466 Index

- specific serotonin reuptake inhibitors (*cont.*)
 drug interactions 175, 206, 244
 history of use 7, 8–9, 16, 19
 metabolism 175, 206
 obsessive–compulsive disorder treatment 172–6,
 203, 205
 augmentation strategies 177
 panic disorder treatment 189, 199, 203, 205, 213
 pervasive developmental disorder treatment 281
 post-traumatic stress disorder treatment 202,
 214
 selective mutism 203
 social phobia treatment 201
 SSRI-induced frontal release 16, 17
 withdrawal syndrome 99–100, 174–5, 206
see also specific drugs
- State-Trait Anxiety Inventory 215
- Steven–Johnson syndrome 17, 122
- stimulants *see* psychostimulants
- streptococcal infections 168–9, 438, 440–1
 and Tourette's syndrome 391, 398
- stress, developmental effects 53–4
- substance abuse 329–30
see also substance use disorder (SUD)
- substance dependence 330–2
- substance P 48
- substance use disorder (SUD) 141, 215, 328–68
 comorbidity 125, 153, 334–7
 in adults 335
 explanatory models 336–7
 implications for research and clinical practice
 336
 treatment 351, 356–7, 361, 364–5, 366–7
- differential diagnosis 108, 137–8
- epidemiology 333–4
- etiology 337
- genetic factors 339–40, 348
- neurobiology 337–49
 brain circuits involved in 340–2
 neurotransmitters/neuropeptides 342–5
- risk factors 338
- tolerance 332
- treatment 125, 349–67
 acute intoxication 350
 agonist substitution therapy 351, 359–61
 alcohol withdrawal 352–7
 cocaine withdrawal 361–3
 comorbid disorders 351, 356–7, 361, 364–5,
 366–7
 decreasing reinforcing effects 350–1, 353–4,
 358–9, 362
 nicotine withdrawal 363–4
 opiates withdrawal 357–61
 pharmacologic deterrents 351, 355
 withdrawal states 350, 352–3, 357–8, 361–2,
 363–4
- sudden death 17–18, 241–2
- suicide 92, 99, 215, 328
- sulpiride
 anorexia nervosa treatment 413
 tic suppression 393, 396
 Sydenham's chorea 168, 391, 398, 438, 441
- talipexole, tic suppression 398
- tardive dyskinesia 151, 152, 205–6, 287–8, 395
- temperament research 197
- temporal lobe, and pervasive developmental
 disorder 274
- testosterone, and aggression 307
- tetrabenzine, tic suppression 389, 393
- tetrahydrocannabinol, anorexia nervosa treatment
 415
- thalamus, and pervasive developmental disorder
 275
- thioridazine 144
- thrombocytopenia 120
- thyroid hormone 49
 depression treatment 96
- thyrotrophin-releasing hormone (TRH) 345
- tiapride
 alcohol abuse treatment 343, 357
 tic suppression 393, 396
- tics 87, 174, 318, 384
 assessment strategies 392
 complex motor tics 384
 complex vocal tics 384
 differential diagnosis 164
 with obsessive–compulsive disorder 161, 162–3,
 167
 psychostimulant effects 239
 simple motor tics 384
 simple vocal tics 384
 treatment 177, 316, 392–401
 alpha-adrenergic agonists 396–7
 dopamine antagonists 394–6
 nonpharmacologic treatment 399
see also Tourette's syndrome (TS)
- tobacco smoking *see* cigarette smoking; substance
 use disorder (SUD)
- tolerance 332
- tomoxetine, ADHD treatment 251
- Tourette's syndrome (TS) 62, 382–402
 central nervous system mechanisms 387–91
 neuroanatomic location 387–8
 neurotransmitters 388–91
 streptococcal infection 391, 398
 comorbidity 162–3, 167–8, 383, 384–6
 ADHD 385, 400
 learning disorders 386
 obsessive–compulsive symptoms 385–6,
 401
 treatment 400–1
 diagnosis 384
 genetic basis 383
 treatment 5, 6, 7, 9, 22, 382–4
 comorbid conditions 400–1
 psychosocial treatment 399–400
see also tics
- Tourette's Syndrome Severity scale (TSSS) 392
- training programs 12–13

467 Index

- transcranial magnetic stimulation 22
 transcription factors, and substance abuse 347–8
 transforming growth factor 49
 tranlycypromine 234, 243
 ADHD treatment 243
 adverse effects 234
 trazodone
 anxiety treatment 356
 depression treatment 96
 pervasive developmental disorder treatment 282
 substance abuse treatment 362
 treatment duration 87–8
 trichotillomania 164
 tricyclic antidepressants (TCAs) 61, 95, 234
 ADHD treatment 3, 240–2, 249
 combined pharmacotherapy 249–50
 and manic symptoms 249
 adverse effects 17, 99, 209, 234, 240
 anorexia nervosa treatment 413
 anxiety disorder treatment 199, 200, 208–10, 218
 depression treatment 16, 97–100, 356
 adults 95–6
 developmentally determined drug response 59
 drug interactions 210, 244
 history of use 4, 7, 19
 post-traumatic stress disorder treatment 202
 substance abuse treatment 356, 362
 withdrawal effects 210
 see also specific drugs
 trifluperazine, pervasive developmental disorder
 treatment 287
 trimipramine 240
 triplet repeat expansion disorders 54–5, 107, 111
 valproate 314
 bipolar disorder maintenance treatment 126
 pervasive developmental disorder treatment
 289
 and polycystic ovary disease 17, 123
 venlafaxine 235
 ADHD treatment 245
 adverse effects 212, 235
 anxiety disorder treatment 200, 204, 212
 generalized anxiety disorder 202, 212, 214
 depression treatment 97, 98, 101
 dosage 204
 social phobia treatment 201
 ventricular enlargement 112, 113
 vigabatrin 314
 Vineland Scale 317
 viqualine, substance abuse treatment 354
 Visual Analog Scale (VAS) 294
 Ward scale of impulsivity 316
 weight gain, and neuroleptics 151
 Wide Range Achievement Test (WRAT) 114
 Wisconsin Card Sorting Test (WISC) 114, 273
 withdrawal syndromes 332, 343
 treatment 350
 alcohol 352–3
 cocaine 361–2
 opiates 357–8
 see also specific drugs; substance use disorder (SUD)
 Wolfram syndrome 22
 Yale–Brown Obsessive–Compulsive Scale
 (Y–BOCS) 165, 317
 Yale Global Tic Severity Scale (TGTSS) 392
 zinc, anorexia nervosa treatment 416–17
 ziprasidone 282